U.S. Launch of CARDAMYST: First FDA-Approved Self-Administered PSVT Treatment

MONTREAL and CHARLOTTE, N.C., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that CARDAMYST™ (etripamil) nasal spray, its first commercial product, is now available through U.S. retail pharmacies. CARDAMYST is a prescription medication indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Implementation of a rapid commercialization plan is underway with a national sales force to be deployed in mid-February 2026.

Milestone Pharmaceuticals has announced the U.S. availability of CARDAMYST (etripamil nasal spray), marking a significant advancement in the treatment of paroxysmal supraventricular tachycardia (PSVT). This innovative medication is the first and only FDA-approved self-administered treatment for adults experiencing episodes of PSVT. The announcement is a culmination of extensive research and development aimed at providing patients with a convenient and effective way to manage their condition.

CARDAMYST works by utilizing etripamil, a fast-acting calcium channel blocker designed to abort PSVT episodes quickly and effectively. The nasal spray formulation offers a rapid onset of action, making it suitable for use at the onset of symptoms, thereby empowering patients to take control of their condition from home without the need for intravenous medications or visits to emergency rooms.

The company’s press release highlights the significance of this launch for both patients and healthcare providers. For patients suffering from PSVT, the availability of an FDA-approved self-administered treatment means that they can respond promptly to their symptoms, potentially reducing the duration and severity of episodes. Furthermore, as healthcare professionals become more aware of this new treatment option, it is expected that they will incorporate CARDAMYST into their management protocols for patients with PSVT.

Milestone Pharmaceuticals is positioning CARDAMYST as a transformative solution for patients who have long dealt with the unpredictability of PSVT episodes. The product is backed by positive clinical trial results that support its effectiveness and safety profile. As awareness increases among healthcare providers, more patients are likely to be prescribed CARDAMYST, enabling them to actively manage their condition.

In addition to its therapeutic benefits, the launch of CARDAMYST also reflects Milestone Pharmaceuticals' commitment to advancing care for patients with cardiovascular conditions. With the introduction of this innovative product, the company aims to continue its growth trajectory and contribute to improving the quality of life for those affected by PSVT.

CARDAMYST is now available at select pharmacies, and the company is actively working to expand its accessibility to ensure that as many patients as possible can benefit from this advancement in PSVT treatment. As more patients gain access to CARDAMYST, it is anticipated that there will be positive shifts in patient experiences and healthcare outcomes related to PSVT.

Overall, the launch of CARDAMYST represents a groundbreaking step in the management of paroxysmal supraventricular tachycardia, offering patients a reliable and convenient option for self-care. As the healthcare community becomes more familiar with this new treatment, it is expected to have a lasting impact on the management of PSVT.